跳至主要内容
临床试验/NCT02805348
NCT02805348已完成不适用

Long-Term Specified Drug Use-Results Survey in Patients With Pre-dialysis Chronic Kidney Disease

Astellas Pharma Inc14 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2016年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
144
试验地点
14
主要终点
Change from baseline in the serum concentrations of phosphate

研究概览

简要总结

The objective of this study is to assess the long-term safety and efficacy of bixalomer under post-marketed setting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time

排除标准

  • 未提供

研究组 & 干预措施

Chronic kidney disease

Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time.

干预措施: Bixalomer (Drug)

结局指标

主要结局

Change from baseline in the serum concentrations of phosphate

时间窗: Baseline and up to Month 12

Change from baseline in the corrected serum concentrations of calcium

时间窗: Baseline and up to Month 12

Change from baseline in the serum concentrations of intact parathyroid hormone

时间窗: Baseline and up to Month 12

Safety assessed by incidence of adverse events

时间窗: Up to Month 12

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验